syndrome is a neurological sensorimotor disorder that is characterized by an irresistible urge to move the lower limbs at rest, and it is frequently accompanied by nocturnal parasthesiae.
syndrome and conditions associated with metabolic dysregulation, sympathoadrenal dysfunction, and cardiovascular disease risk: A systematicreview.
syndrome assessment: All participants were evaluated by a face-to-face interview to determine the presence of RLS according to the revised IRLSSG criteria.
Prevalence and disease burden of primary restless legs
syndrome: results of a general population survey in the United States.
Prado, "Translation and validation into the Brazilian Portuguese of the restless legs
syndrome rating scale of the International Restless Legs
Syndrome Study Group," Arquivos de Neuro-Psiquiatria, vol.
syndrome (RLS) is a progressive and chronic disorder manifested by a burning sensation and paresthesia, and is characterized by a requirement of moving the affected extremities when at rest and during the night (Allen et al, 2003; American Sleep Disorders Association, 1997; Walters, 1995).
Key words: Multiple sclerosis--epidemiology; Restless legs
syndrome--diagnosis; Hospitals, special; Croatia
Among such movements, the occurrence of restless legs
syndrome (RLS) is most frequent.
Changes of cortical excitability after dopaminergic treatment in restless legs
The special criteria for diagnosis of RLS have been introduced by the international restless legs
syndrome study group (IRLSSG) and including; 1) a uncontrolled urge to frequently move the limbs due to RLS symptoms, 2) temporary relief of the unpleasant symptoms by moving; 3) worsening of the symptoms after resting or lack of movement, 4) worsening of the symptoms in the evening or at night (8).
Conclusion: Restless leg
syndrome was more common in women and the most common complaint was insomnia.
- Canadian patients suffering from Restless Legs
Syndrome will have access to Relaxis, a medical device approved by the US Food and Drug Administration for treating the symptoms of primary RLS, due to an exclusive new agreement between Sleep Therapeutics and Sensory NeuroStimulation Inc., maker of the Relaxis technology, the companies said on Wednesday.